Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Memantine Targeting Neurovascular Dysfunction After Mild and Moderate Traumatic Brain Injury-A Randomized Feasibility Trial (MEND)

NCT07867210 is registered in ClinicalTrials.gov with Nova Scotia Health Authority as lead sponsor.

NCT NCT07867210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07867210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Memantine Targeting Neurovascular Dysfunction After Mild and Moderate Traumatic Brain Injury-A Randomized Feasibility Trial (MEND)
Lead sponsor
Nova Scotia Health Authority
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2027
Completion date
March 31, 2030
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild traumatic brain injury, moderate traumatic brain injury (tbi), tbi, traumatic brain injury